SURVIVE

Integrating cancer detection and SURgery Via molecular Imaging

Coordinatore	ACADEMISCH ZIEKENHUIS LEIDEN    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	2˙487˙600 €
EC contributo	2˙487˙600 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-ADG_20120314
Funding Scheme	ERC-AG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-11-01   -   2018-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Ms. Nome: Nancy Cognome: Koot Email: send email Telefono: +31 71 526 2513	NL (LEIDEN)	hostInstitution	2˙487˙600.00
2	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Prof. Nome: Cornelis Jan Hadde Cognome: Van De Velde Email: send email Telefono: +31 71 5262309 Fax: +31 71 5266750	NL (LEIDEN)	hostInstitution	2˙487˙600.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The ambitious aim of this ERC-advanced grant proposal is to develop strategies that will connect cancer detection and surgery via tumor-specific molecular imaging techniques. This will lead to personalized patient-, or even tumor-specific treatment strategies. In addition, it will provide a tool for the selection of patients that, following preoperative (neoadjuvant) treatment, would benefit from additional (minimally invasive) surgery and identify patients who may be treated non-operatively. Fine-tuning the relation between tumor diagnosis, neoadjuvant treatment, preoperative planning and minimally invasive image-guided surgery will likely improve radical oncologic surgery while reducing surgical morbidity in cancer patients.

The mechanistic aim of the proposal is to develop an integrated multimodal imaging strategy that will more accurately connect tumor biology with surgical resection approaches via the use of tumor-specific molecular imaging agents. The cornerstone of this approach is the unique clinical translation of tumor-targeted imaging agents that are both radioactive (diagnostic imaging) and fluorescently (surgical guidance) labeled. It is expected that the proposed multimodal imaging agents will allow for a significant improvement of both imaging and surgery strategies.'